Terhi Savinko

Terhi Savinko

Auto-generated profile, based on publicly available information

Terhi Savinko

Institute of Biotechnology, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FCFerda Cevikbas
Ferda Cevikbas
XWXidao Wang
Xidao Wang
TATasuku Akiyama
Tasuku Akiyama
CKCordula Kempkes
Cordula Kempkes
TSTerhi Savinko
Terhi Savinko
MSMartin Steinhoff
Martin Steinhoff

19 August 2016 in Circulation Research
Verified
Journal Article
Open access
PDF file
ACAmy R. Cameron
Amy R. Cameron
VMVicky L. Morrison
Vicky L. Morrison
DLDaniel Levin
Daniel Levin
MMMohapradeep Mohan
Mohapradeep Mohan
CFCalum Forteath
Calum Forteath
GRGraham Rena
Graham Rena
Rationale:: The diabetes mellitus drug metformin is under investigation in cardiovascular disease, but the molecular mechanisms underlying possible benefits are poorly understood. Objective:: Here, we have studied anti-inflammatory effects of the drug and their relationship to antihyperglycemic properties. Methods and Results:: In primary hepatocytes from healthy animals, metformin and the IKKβ (inhibitor of kappa B kinase) inhibitor BI605906 both inhibited tumor necrosis factor-α–dependent IκB degradation and expression of proinflammatory mediators interleukin-6, interleukin-1β, and CXCL1/2 (C-X-C motif ligand 1/2). Metformin suppressed IKKα/β activation, an effect that could be separated from some metabolic actions, in that BI605906 did not mimic effects of metformin on lipogenic gene expression, glucose production, and AMP-activated protein kinase activation. Equally AMP-activated protein kinase was not required either for mitochondrial suppression of IκB degradation. Consistent with discrete anti-inflammatory actions, in macrophages, metformin specifically blunted secretion of proinflammatory cytokines, without inhibiting M1/M2 differentiation or activation. In a large treatment naive diabetes mellitus population cohort, we observed differences in the systemic inflammation marker, neutrophil to lymphocyte ratio, after incident treatment with either metformin or sulfonylurea monotherapy. Compared with sulfonylurea exposure, metformin reduced the mean log-transformed neutrophil to lymphocyte ratio after 8 to 16 months by 0.09 U (95% confidence interval, 0.02–0.17; P =0.013) and increased the likelihood that neutrophil to lymphocyte ratio would be lower than baseline after 8 to 16 months (odds ratio, 1.83; 95% confidence interval, 1.22–2.75; P =0.00364). Following up these findings in a double-blind placebo controlled trial in nondiabetic heart failure (trial registration: NCT00473876), metformin suppressed plasma cytokines including the aging-associated cytokine CCL11 (C-C motif chemokine ligand 11). Conclusion:: We conclude that anti-inflammatory properties of metformin are exerted irrespective of diabetes mellitus status. This may accelerate investigation of drug utility in nondiabetic cardiovascular disease groups. Clinical Trial Registration:: Name of the trial registry: TAYSIDE trial (Metformin in Insulin Resistant Left Ventricular [LV] Dysfunction). URL: https://www.clinicaltrials.gov . Unique identifier: NCT00473876.

1 May 2012 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TSTerhi Savinko
Terhi Savinko
SMSampsa Matikainen
Sampsa Matikainen
USUlpu Saarialho-Kere
Ulpu Saarialho-Kere
MLMaili Lehto
Maili Lehto
GWGuoying Wang
Guoying Wang
HAHarri Alenius
Harri Alenius

1 September 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ESEnikö Sonkoly
Enikö Sonkoly
PJPeter Janson
Peter Janson
MMMarja-Leena Majuri
Marja-Leena Majuri
TSTerhi Savinko
Terhi Savinko
NFNanna Fyhrquist
Nanna Fyhrquist
APAndor Pivarcsi
Andor Pivarcsi

1 December 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
NFNanna Fyhrquist
Nanna Fyhrquist
LRLasse Ruokolainen
Lasse Ruokolainen
ASAlina Suomalainen
Alina Suomalainen
SLSari Lehtimäki
Sari Lehtimäki
VVVille Veckman
Ville Veckman
HAHarri Alenius
Harri Alenius

14 August 2014 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
MIMarit Ilves
Marit Ilves
JPJaana Palomäki
Jaana Palomäki
MVMinnamari Vippola
Minnamari Vippola
MLMaili Lehto
Maili Lehto
KSKai Savolainen
Kai Savolainen
HAHarri Alenius
Harri Alenius
Metal oxide nanoparticles such as ZnO are used in sunscreens as they improve their optical properties against the UV-light that causes dermal damage and skin cancer. However, the hazardous properties of the particles used as UV-filters in the sunscreens and applied to the skin have remained uncharacterized.